NIH trial of anti-CD14 antibody to treat COVID-19 respiratory disease begins
The study will enroll between 300 and 350 hospitalized COVID-19 patients aged 18 years or older at 10 to 15 sites nationwide.
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news
More News: American Health | COVID-19 | National Institutes of Health (NIH) | Respiratory Medicine | Study